# Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate

> **NCT00369304** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** pharmacokinetic (how the body absorbs and eliminates) interaction

## Key facts

- **NCT ID:** NCT00369304
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** — (—)
- **Last updated:** 2009-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369304, "Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00369304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*